(IN BRIEF) Evotec SE has announced that Esperion Therapeutics has nominated an oral preclinical development candidate for primary sclerosing cholangitis (PSC), marking a major milestone in their collaboration. The PDC, developed through Evotec’s integrated small molecule discovery platform and Esperion’s … Read the full press release
Posted in Business, Germany, Government, Healthcare, News, Pharma & Biotech, Science, Technology
Tagged ACLY biology, bile ducts, clinical development, collaboration, Cord Dohrmann, drug discovery, Esperion Therapeutics, Evotec Advances Collaboration with Esperion as New ACLY-Based Candidate Targets Primary Sclerosing Cholangitis, Evotec and Esperion Advance Novel Treatment Candidate for Primary Sclerosing Cholangitis, Evotec INDiGO, Evotec SE, fibrosis, Frankfurt Stock Exchange EVT, hepatology, IND-enabling platform, liver disease, milestone payment, NASDAQ ESPR, NASDAQ EVO, preclinical development candidate, primary sclerosing cholangitis, PSC, rare diseases
(IN BRIEF) The EIB has extended a €150 million loan to Alfasigma to fund its R&D efforts from 2025 to 2027, targeting new drugs in gastroenterology, hepatology, vascular medicine, rheumatology, and rare diseases. The financing, endorsed by EIB Vice-President Gelsomina … Read the full press release
Posted in Banks, Business, Economy, Financial, Government, Healthcare, Industrial, Investment, Italy, Luxembourg, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Alfasigma, biopharmaceutical innovation, EIB, European competitiveness, European Investment Bank, gastroenterology, Gelsomina Vigliotti, hepatology, job creation, partnership, patient-centred therapies, R&D financing, rare diseases, rheumatology, specialty care, Tatiana Simonelli, Vascular Medicine
(PRESS RELEASE) HOERSHOLM, Denmark, 12-Sep-2022 — /EuropaWire/ — Chr Hansen Holding A/S (CPH: CHR), a Danish bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries, has announced new regulatory approvals around the world for … Read the full press release
Posted in Denmark, Food & Beverage, Healthcare, Pharma & Biotech, Science
Tagged 2’-FL, 2’-fucosyllactose, 3-FL, 3-fucosyllactose, 3’-sialyllactose, 3’-SL, 6’-sialyllactose, 6’-SL, breast milk, breastfeeding, Chr. Hansen, EFSA, European Food Safety Authority, FDA, Generally Recognized as Safe, GRAS, hepatology, HMOs, Human Milk Oligosaccharides, infant formula, infant health, infant microbiome science, Jesper Sig Mathiasen, lacto-N-tetraose, LNT, NASPGHAN 2022, Novel Food approval, Nutrition, pediatric gastroenterologists, pediatric gastroenterology, WHO, World Health Organization
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?